Clinical efficacy and safety trial of adding Tanreqing Injection for pediatric lobar pneumonia (sputum heat closed lung syndrome)

Phase 4

Not yet recruiting

• Conditions: Mycoplasma pneumoniae pneumonia in children presenting with lobar pneumonia

• Registration Number: ITMCTR2023000060
• Lead Sponsor: YANCHENG NO.1 PEOPLE'S HOSPITA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-12-18

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Inpatients who meet the Western medicine diagnostic criteria of Mycoplasma pneumoniae pneumonia in children presenting with lobar pneumonia;
(2) Meet the diagnostic criteria of TCM syndrome differentiation, phlegm, heat and closed lung syndrome;
(3) Between 2 and 14 years old, without gender limitation;
(4) The legal guardian understands and signs the informed consent form (children aged 10 years old and above who can understand and sign their own name should also sign it).

Exclusion Criteria

(1) Patients with other respiratory diseases except mycoplasma pneumoniae pneumonia manifested by lobar pneumonia;
(2) Patients with severe primary diseases and mental diseases such as heart (congenital heart disease, myocarditis, etc.), liver (upper limit of AST and ALT), kidney (BUN, upper limit of Scr> normal value) and hematopoietic system (anemia above moderate degree);
(3) Serious abnormal blood oxygen saturation (<85%);
(4) People who are allergic to the recommended use of drugs;
(5) Children with acute infectious diseases such as measles and pertussis;
(6) Children with severe malnutrition and immunodeficiency;
(7) Patients who have participated in or are participating in the clinical trials of other drugs within the past one month;
(8) The investigator is not unsuitable for inclusion in the clinical trial.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified